HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor maintains a 'Buy' rating on Tyra Biosciences (NASDAQ:TYRA) but lowers the price target from $20 to $19.
November 08, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Tyra Biosciences' price target has been lowered from $20 to $19 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The news is directly about Tyra Biosciences and is likely to influence investor sentiment. The lowering of the price target might be seen as a negative signal, but the maintained 'Buy' rating indicates continued confidence in the company's prospects. The net impact on the stock price is uncertain in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100